In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
E.U. Leaders Lean Toward Negotiating, Not Retaliating, Over Trump Threat Faced with the threat of steep tariffs by President Trump over Greenland, European leaders began to coalesce around a strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback